Pfizer Improving the care and outcomes of residents of Canada living with metastatic NSCLC RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Tuesday 23rd, April 2024
External Deadline: Tuesday 30th, April 2024
Description
Pfizer, the Lung Health Foundation (LHF), Lung Cancer Canada (LCC), and the Quebec Lung Association (QLA) are jointly issuing a Quality Improvement Request for Proposal (RFP). Grant funding and general oversight of the funded projects will be provided directly from Pfizer on behalf of Pfizer and the collaborators.
For all grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. As the commercial supporter, Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the project.
Date RFP Issued: February 27, 2024
Geographic Scope: Canada
Clinical Area: Metastatic non-small cell lung cancer (NSCLC)
Link to full RFP: Improving the care and outcomes of residents of Canada living with metastatic NSCLC
Application Due Date: April 30, 2024
Specific Area of Interest: The goal of this RFP is to improve health equity for residents of Canada living with metastatic NSCLC by addressing challenges such as, but not limited to:
- – Disparities linked to age, race, geography, income or other factors
- – Implementation of value-based healthcare to improve quality of care for individuals living with NSCLC
- – Encouraging the use of multidisciplinary care models (e.g., nurse navigator, palliative care, psychological/mental health support)
– Approaches to optimize care throughout the cancer experience of individuals living with NSCLC, including optimal access to clinical trials and evidence-based treatment - Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Don Rodriguez, Grant Officer (Don.Rodriguez@pfizer.com).